A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback